When Prescription Cost Becomes a Barrier to Treatment Adherence

You've diagnosed your patient with interdigital tinea pedis that hasn't responded to OTC antifungals, and Ertaczo (Sertaconazole Nitrate 2%) is the right clinical choice. But when the pharmacy quotes $897 to $1,070 for a single tube, there's a real chance your patient won't fill the prescription — or will abandon treatment early to stretch their supply.

Medication cost is one of the most significant and underaddressed barriers to treatment adherence. According to multiple studies, patients who face high out-of-pocket costs are significantly less likely to fill prescriptions, adhere to treatment regimens, or follow up as directed. For a topical antifungal that requires a full 4-week course applied twice daily, the stakes are clear: patients who can't afford Ertaczo won't complete treatment, and their fungal infection will persist or recur.

This guide equips providers with practical strategies to help patients access Ertaczo affordably — or find appropriate alternatives when cost is prohibitive.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you anticipate patient barriers before they arise:

Cash Prices

• Brand Ertaczo: $897–$1,070 per tube at most retail pharmacies
• No generic available: Sertaconazole Nitrate has no FDA-approved generic version in the United States, eliminating the most common cost-reduction pathway

Insurance Coverage

• Most commercial insurance plans and Medicare Part D cover Ertaczo, but often with significant restrictions
• Prior authorization is frequently required, with documentation of failed OTC therapy (Clotrimazole, Terbinafine) typically needed
• Step therapy requirements are common — insurers may require trial and failure of one or more formulary alternatives before approving Ertaczo
• Even with coverage, patients on high-deductible health plans may face the full cash price until their deductible is met
• Some plans classify Ertaczo as a non-preferred brand, resulting in higher tier copays ($75–$150+)

The Real Impact

When a patient with a $5,000 deductible is prescribed Ertaczo in January, they're essentially paying cash price. This is the reality for millions of patients on high-deductible plans, and it's worth factoring into your prescribing decisions early in the conversation.

Manufacturer Savings Programs

Manufacturer-sponsored savings can significantly reduce out-of-pocket costs for eligible patients:

GoodRx and InsideRx Partnership

GoodRx has partnered with InsideRx and Ertaczo's manufacturer to offer discount pricing:

• Coupons available through GoodRx can bring the price down to approximately $447–$897 depending on the pharmacy
• Patients can access these coupons at goodrx.com or through the GoodRx app
• No insurance required — these work for commercially insured, underinsured, and uninsured patients
• Can be presented at the pharmacy counter alongside or instead of insurance

Limitations

• Savings may vary by pharmacy location and current program availability
• Government-insured patients (Medicare, Medicaid, Tricare) are typically not eligible for manufacturer copay assistance per federal anti-kickback regulations
• Programs can be discontinued or modified at the manufacturer's discretion

Coupon and Discount Card Programs

Several third-party discount programs offer savings on Ertaczo. Consider recommending these to patients or having your staff provide information at the point of prescribing:

Major Discount Card Options

• GoodRx — The most widely used platform; shows pricing at multiple pharmacies and provides printable or digital coupons. Ertaczo prices may drop to $447–$897 with GoodRx coupons.
• SingleCare — Another popular discount card accepted at most major pharmacies. Free to use, no registration required.
• InsideRx — Partners directly with manufacturers for brand-name savings. Particularly useful for Ertaczo given the manufacturer partnership.
• RxSaver — Compares prices across local pharmacies with available coupons.
• BuzzRx — Free discount card with pharmacy price comparison tools.

How to Integrate Into Workflow

• Keep QR codes or links to GoodRx, SingleCare, and InsideRx in your prescribing workflow or EHR quick-text templates
• Train front desk and medical assistant staff to provide discount card information when scheduling follow-ups for dermatology patients
• Include a printed handout with your prescription that lists 2–3 discount card options with instructions

Patient Assistance Programs

For patients experiencing financial hardship — particularly the uninsured or underinsured — patient assistance programs (PAPs) may be an option:

• NeedyMeds (needymeds.org) — Comprehensive database of patient assistance programs, discount cards, and disease-specific financial aid
• RxAssist (rxassist.org) — Patient assistance program database maintained by Volunteers in Health Care
• RxHope (rxhope.com) — Helps connect patients and providers with pharmaceutical company assistance programs

Note: Ertaczo does not have a widely publicized manufacturer-sponsored patient assistance program at this time. These resources may still surface alternative assistance options or state-specific programs that can help.

Generic Alternatives and Therapeutic Substitution

When Ertaczo's cost is genuinely prohibitive and no savings program bridges the gap, therapeutic substitution is a clinically sound approach. Consider these alternatives based on the clinical scenario:

First-Line OTC Options (If Not Already Tried)

• Terbinafine (Lamisil) — OTC allylamine antifungal, under $15. Applied once or twice daily for 1–4 weeks. Effective for most tinea pedis cases.
• Clotrimazole (Lotrimin) — OTC azole antifungal, $8–$15. Applied twice daily for 2–4 weeks. Well-established efficacy.

Prescription Alternatives

• Naftifine (Naftin) — Prescription allylamine antifungal cream or gel. Generic available, making it significantly more affordable than Ertaczo. Applied once or twice daily for 2–4 weeks. Brand: $400–$700; generic substantially less.
• Luliconazole (Luzu) — Prescription azole antifungal cream, applied once daily for 2 weeks (shorter course). Brand: $500–$800. No generic available.
• Econazole (Spectazole) — Older prescription azole antifungal with generic available. An affordable prescription option.
• Ciclopirox — Prescription antifungal with a different mechanism (hydroxypyridone class). Generic available and more affordable.

When to Stick with Ertaczo

Ertaczo's dual mechanism of action (ergosterol inhibition plus direct membrane binding) and anti-inflammatory properties via the p38-COX-2-PGE2 pathway make it particularly valuable when:

• The patient has failed OTC antifungals and first-line prescriptions
• Significant inflammation accompanies the fungal infection
• Cross-class therapy is desired (prior allylamine failure → try imidazole)
• The patient has access to adequate savings to make cost manageable

For a comprehensive overview of alternatives, refer patients to our guide to Ertaczo alternatives.

Building Cost Conversations Into Your Workflow

Proactive cost discussions improve adherence, reduce prescription abandonment, and build patient trust. Here are practical approaches:

At the Point of Prescribing

• Ask about cost concerns directly: "This medication can be expensive. Let's talk about how to make it affordable before I send it to the pharmacy."
• Check formulary status using your EHR's formulary lookup tool before prescribing — if Ertaczo requires PA, start the process immediately or consider a covered alternative
• Mention discount cards proactively: "I'm going to prescribe Ertaczo. Before you fill it, check GoodRx or SingleCare — you may save several hundred dollars."

Prior Authorization Best Practices

• Document failed OTC therapy clearly in your clinical notes — this is typically required for PA approval
• Include specific product names, duration of use, and clinical outcome of each failed trial
• Submit PA proactively rather than waiting for pharmacy rejection
• Appeal denials with clinical rationale for why alternatives are insufficient

Follow-Up

• At the 2-week follow-up, ask whether the patient has been able to fill the prescription and adhere to twice-daily application
• If cost prevented filling, troubleshoot together — explore discount cards, PA appeals, or therapeutic substitution
• Consider switching to a shorter-course alternative (like Luliconazole's 2-week regimen) if adherence to a 4-week course is a concern

Staff Training

• Train staff to provide discount card information and pharmacy navigation resources at checkout
• Consider partnering with Medfinder for Providers to help patients locate Ertaczo in stock and compare pharmacy pricing
• Create a standard handout for expensive prescriptions that includes discount card QR codes and patient assistance program websites

Final Thoughts

Ertaczo is a clinically effective antifungal with a unique dual mechanism of action, but its $897–$1,070 price tag and brand-only status create genuine access barriers. By proactively addressing cost at the point of prescribing — through discount cards, manufacturer savings, prior authorization strategies, and thoughtful therapeutic substitution when appropriate — you can significantly improve the odds that your patients complete treatment and achieve lasting resolution of their fungal infection.

For more clinical resources on Ertaczo, including shortage updates for providers and how to help patients find Ertaczo in stock, visit our provider resource library at medfinder.com/providers.